ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Operating Margin
- Operating margin · 12 months: Value -12.16%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -12.16% | Operating income / revenue. Period ending 2026-06-30. $-37.46M ÷ $308.08M × 100 ≈ -12.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -37.46M USD | Operating Income (Loss) |
| Revenue | 308.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 75.25M USD | Cost of Goods and Services Sold |
| Research and development | 88.21M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-37.46M | $308.08M | $75.25M | $88.21M | (m) | -12.16% |
| 2026-03-31 | $-46.73M | $295.41M | $73.09M | $93.19M | (m) | -15.82% |
| 2025-12-31 | $-57.12M | $276.98M | $71.36M | $93.77M | (m) | -20.62% |
| 2025-09-30 | $-78.19M | $252.75M | $71.18M | $95.20M | (m) | -30.93% |
| 2025-06-30 | $-121.11M | $205.22M | $69.69M | $95.69M | (m) | -59.02% |
| 2025-03-31 | $-143.39M | $189.53M | $71.01M | $96.91M | (m) | -75.66% |
| 2024-12-31 | $-162.55M | $178.96M | $72.08M | $102.95M | (m) | -90.83% |
| 2024-09-30 | $-199.78M | $177.28M | $73.65M | $108.51M | (m) | -112.69% |
| 2024-06-30 | $-218.10M | $168.77M | $76.33M | $112.88M | (m) | -129.23% |
| 2024-03-31 | $-218.60M | $174.50M | $74.92M | $119.76M | (m) | -125.27% |
| 2023-12-31 | $-227.03M | $170.28M | $75.55M | $122.12M | (m) | -133.33% |
| 2023-09-30 | $-195.15M | $179.69M | $72.53M | $124.59M | (m) | -108.61% |
| 2023-06-30 | $-189.63M | $189.60M | $68.09M | $131.72M | (m) | -100.01% |
| 2023-03-31 | $-194.31M | $184.34M | $63.40M | $136.52M | (m) | -105.41% |
| 2022-12-31 | $-200.19M | $185.31M | $57.91M | $141.76M | (m) | -108.03% |
| 2022-09-30 | $-222.60M | $168.04M | $55.68M | $145.23M | (m) | -132.47% |
| 2022-06-30 | $-233.49M | $159.68M | $54.96M | $145.65M | (m) | -146.23% |
| 2022-03-31 | $-230.75M | $154.52M | $52.50M | $146.41M | (m) | -149.33% |
| 2021-12-31 | $-208.97M | $154.34M | $49.30M | $142.34M | (m) | -135.39% |
| 2021-09-30 | $-191.61M | $146.60M | $41.17M | $143.47M | (m) | -130.70% |
| 2021-06-30 | $-172.33M | $133.43M | $33.03M | $137.72M | (m) | -129.16% |
| 2021-03-31 | $-159.48M | $115.91M | $27.18M | $125.91M | (m) | -137.58% |
| 2020-12-31 | $-152.82M | $98.38M | $22.53M | $116.07M | (m) | -155.33% |
| 2020-09-30 | $-132.77M | $92.41M | $22.26M | $101.43M | (m) | -143.68% |
| 2020-06-30 | $-113.77M | $92.17M | $21.81M | $91.62M | (m) | -123.44% |
| 2020-03-31 | $-92.97M | $93.31M | $22.63M | $82.16M | (m) | -99.63% |
| 2019-12-31 | $-78.39M | $85.07M | $22.27M | $70.70M | (m) | -92.15% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-49.76M | $55.66M | $19.67M | $39.16M | (m) | -89.39% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-44.48M | $38.45M | $15.68M | $32.00M | (m) | -115.68% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |